Breed · Dog

Lhasa Apso: adverse event reports

FDA breed label "Lhasa Apso" · single-breed animals only

Read this first · FDA's caveat, in its words

An API dataset query result cannot be used to estimate the risk associated with the product or compare one drug or device product with another. When looking at the results, be aware that there is no certainty that the reported drug or device caused the adverse event. This dataset should not be the sole source of information for clinical decision-making or other assumptions about the safety or effectiveness of a product. The adverse event may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources. FDA Center for Veterinary Medicine

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.

Not veterinary advice. This site lists what was reported to FDA. For an animal that is unwell, contact a veterinarian.

3,893reports, 1987–20260.4% of dog reports

63reports, 12 months to March 202673 in the 12 months before

33.7%classed serious, as reportedall dogs: 38.3%

13%name milbemycin oxime + spinosadall dogs: 13.1%

FDA's database holds 3,893 reports where the animal's breed is given as "Lhasa Apso", shown here as Lhasa Apso: 0.4% of reports about dogs. Reports on crossbred animals are left out of breed pages.

63 reports arrived in the 12 months to March 2026, down 14% from 73 in the 12 months before. A breed's count mostly mirrors how common the breed is; registration and ownership figures by breed are not public data, so no per-animal rate can be given.

By active ingredient, the drugs named most often are milbemycin oxime + spinosad, spinosad and ivermectin + pyrantel pamoate. Milbemycin Oxime + Spinosad is named in 13% of this breed's reports, about the same share as in reports about all dogs (13.1%).

The terms listed most often are vomiting (22.6%), emesis (8.9%) and diarrhoea (7.9%). Vomiting appears in 22.6% of reports, about the same share as in all dog reports (19.7%). 33.7% of reports stating seriousness were classed as serious, against 38.3% for dogs overall.

Drugs named most often, by active ingredient

Active ingredients recorded for the drug	Reports	Share of Lhasa Apso reports	Share of all dog reports
Milbemycin Oxime + Spinosad	508	13%	13.1%
Spinosad	360	9.2%	5.8%
Ivermectin + Pyrantel Pamoate	295	7.6%	14.9%
Afoxolaner	291	7.5%	5.7%
Carprofen	231	5.9%	4.8%
Cyclosporine	221	5.7%	1.5%
Selamectin	214	5.5%	3%
Fluralaner	203	5.2%	6.7%
Oclacitinib	150	3.9%	2.9%
Moxidectin	123	3.2%	5%
Selegiline Hydrochloride	96	2.5%	0.4%
Trilostane	82	2.1%	1.2%
Lufenuron + Milbemycin Oxime	81	2.1%	2.7%
Milbemycin Oxime	72	1.8%	3%
Insulin	69	1.8%	0.7%
Imidacloprid + Moxidectin	52	1.3%	1.3%
Ivermectin	51	1.3%	1.3%
Ivermectin + Praziquantel + Pyrantel Pamoate	51	1.3%	0.9%
(S) - methoprene	49	1.3%	0.6%
Pyrantel Pamoate + Sarolaner	47	1.2%	5.1%

Ordered by report count. Differences from the species column often come from body size (which drugs a breed is prescribed) and from how common the breed was in the years a drug sold most. FDA states that these data cannot be used to estimate risk or to compare one product with another. Brand and manufacturer names are masked by FDA in these records.

Signs listed in reports

share of Lhasa Apso reports listing the termall dog reports

Vomiting22.6%879
Emesis[vomiting]8.9%347
Diarrhoea[diarrhea]7.9%306
Anorexia[not eating]7.5%292
Lethargy[unusually tired or inactive]7.4%287
Depression[dull, quiet or withdrawn]6.9%269
Lack of efficacy (ectoparasite) - flea[the product did not have the expected effect: fleas]6.7%261
Pruritus[itching]3.9%153
Elevated serum alkaline phosphatase (SAP)[a liver and bone enzyme above the normal range]3.7%144
Lack of efficacy - NOS[the product did not have the expected effect]3.7%144
Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]3.6%141
Death3.4%133
Lack of efficacy (endoparasite) - hookworm[the product did not have the expected effect: hookworms]3.1%122
Death by euthanasia[the animal was euthanized]2.6%102
Ineffective, heartworm larvae[legacy FDA term: the product did not have the expected effect (heartworm larvae)]2.4%95
Ataxia[unsteady, uncoordinated movement]2.4%94
Seizure NOS[seizure, type not specified]2.2%86
Polydipsia[drinking more than usual]2.2%85
Convulsion[seizure]2%76
Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]1.9%75
Lack of efficacy (tick)[the product did not have the expected effect: ticks]1.9%74
Bloody diarrhoea[diarrhea with blood]1.8%71
Behavioural disorder NOS[behaviour change, type not specified]1.7%68
Polyuria[passing more urine than usual]1.7%68
Trembling1.7%68

Age and weight

Age of the animal

Under 1 year5.9%228

1 to 3 years18.1%705

4 to 7 years23.8%925

8 to 11 years25.1%979

12 years and over22.8%887

Age not given4.3%169

Weight of the animal

Under 5 kg (11 lb)8.6%336

5 to 9.9 kg (11–22 lb)66.3%2,582

10 to 24.9 kg (22–55 lb)21.1%823

25 to 44.9 kg (55–99 lb)0.1%3

45 kg and over (99 lb+)0%0

Weight not given3.8%149

Coloured bar: Lhasa Apso reports. Grey bar: all dog reports.

Trend and outcomes

Reports by month FDA received them. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Outcome recorded in the report

Recovered/Normal24.6%958

Recovered with Sequela2.5%97

Ongoing12.2%473

Died5.2%202

Euthanized1.1%43

Outcome Unknown18.1%704

Beside all dogs

Measure	Lhasa Apso	All dogs
Reports	3,893	985,675
Latest 12 months	63	53,292
Classed serious, of reports stating it	33.7%	38.3%
Death or euthanasia recorded, per 1,000 reports	62.9	55

Questions about Lhasa Apso reports

How many FDA adverse event reports involve Lhasa Apsos?

3,893 reports through March 2026, 0.4% of reports about dogs; 63 in the latest 12 months.

Which drugs are named most often in Lhasa Apso reports?

By active ingredient: milbemycin oxime + spinosad (508), spinosad (360), ivermectin + pyrantel pamoate (295), afoxolaner (291) and carprofen (231). Brands are masked in the public data.

What signs are reported most for this breed?

vomiting (22.6%), emesis (8.9%), diarrhoea (7.9%), anorexia (7.5%) and lethargy (7.4%).

Is the Lhasa Apso more sensitive to certain drugs?

Report counts cannot answer that. They show what was reported, not what a drug did, and they are not adjusted for how many Lhasa Apso animals exist or were treated. Breed-related drug sensitivities that are established are described on FDA-approved labels; a veterinarian is the person to ask about an individual animal.

Why are crossbreds not included?

FDA records crossbred animals with one or more component breeds. Counting them under each component would double count, so breed pages use single-breed reports only. Crossbreds remain in the species totals.

How do I report a problem?

Call the drug company using the number on the label, or send Form FDA 1932a to FDA. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Breed names are FDA's labels rearranged into everyday order ("Lhasa Apso" becomes "Lhasa Apso"). No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.